Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
08:30am, Wednesday, 01'st May 2024
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
05:20pm, Monday, 15'th Apr 2024
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 202
Aileron Therapeutics Announces CEO Transition
08:00am, Tuesday, 12'th Mar 2024
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medi
Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 Topl
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
04:30pm, Thursday, 01'st Feb 2024
Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis Panel discussion will highlight LTI-03, Aileron's novel Caveolin-
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
12:30pm, Tuesday, 31'st Oct 2023
Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IP
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
11:24am, Tuesday, 04'th Apr 2023
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnin
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
11:26am, Tuesday, 14'th Mar 2023
Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agr
S&P 500 Down 2%; Mobilicom Shares Spike Higher
07:24pm, Tuesday, 21'st Feb 2023 Benzinga
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday.
The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The S&P
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
07:07pm, Tuesday, 21'st Feb 2023 Benzinga
Gainers
Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Ambrx Biopharma Inc. (NY
Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February
05:10pm, Tuesday, 21'st Feb 2023 Benzinga
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 500 points on Tuesday.
The Dow traded down 1.61% to 33,280.92 while the NASDAQ fell 2.05% to 11,545.79. The S&P 5
Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast
03:15pm, Tuesday, 21'st Feb 2023 Benzinga
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday.
Following the market opening Tuesday, The Dow traded down 1.15% to 33,438.86 while the NASDAQ
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
01:30pm, Tuesday, 21'st Feb 2023 GlobeNewswire Inc.
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
05:00pm, Thursday, 29'th Dec 2022 Zacks Investment Research
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
01:32pm, Thursday, 29'th Dec 2022
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
